Clinical trial NCT02546960 (phase 2, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant must be in stable health. Participants may have underlying illnesses such
             as hypertension, diabetes, ischemic heart disease, hyperlipoproteinemia, or
             hypothyroidism, as long as their symptoms/signs are medically controlled. If they are
             on medication for a condition, the medication dose must have been stable for at least
             12 weeks preceding vaccination and is expected to remain stable for the duration of
             the study

          -  Participant must meet the protocol defined laboratory criteria within 12 days before
             Day 1

          -  Participant must be able to attend all scheduled visits and to comply with all study
             procedures

          -  Participant must have a body mass index (BMI) of less than or equal to (<=) 35
             kilogram per square meter (kg/m^2)

          -  A woman of childbearing potential must have a negative urine pregnancy test on Day 1
             before vaccination

        Exclusion Criteria:

          -  Participant is a woman who is pregnant, breast-feeding, or has a positive urine
             pregnancy test on Day 1 before vaccination, or is planning to become pregnant 3 months
             after study vaccine administration or within 3 months after study vaccine
             administration, or subject is a man who plans to father a child while enrolled in this
             study or within 3 months after study vaccine administration

          -  Participant has an acute illness, acute infection, or fever (body temperature greater
             than or equal to [>=] 38 degree Celsius)

          -  Participant has a serious chronic disorder, including severe chronic obstructive
             pulmonary disease or clinically significant congestive heart failure, requirement for
             supplemental oxygen, end stage renal disease with or without dialysis, clinically
             unstable cardiac disease, or has any condition for which, in the opinion of the
             investigator, participation would not be in the best interest of the subject (example
             compromise the well-being) or that could prevent, limit, or confound the
             protocol-specified assessments

          -  Participant has a history of neoplastic disease (excluding non-melanoma skin cancer
             that was successfully treated) within the past 5 years or a history of any
             hematological malignancy

          -  Participant has known or suspected congenital or acquired immunodeficiency (including
             leukemia, HIV seropositivity), has received immunosuppressive therapy (such as
             anti-cancer chemotherapy, radiation therapy or cytotoxic drugs), within the preceding
             6 months; or long-term systemic corticosteroid therapy [prednisone or equivalent for
             more than 2 consecutive weeks within the past 3 months]), or has chronic active
             hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and
             hepatitis C antibody, respectively